To assess open-label adjunctive topiramate in the treatment of outpatients with unstable bipolar disorder (BD).
B ipolar disorder is a highly prevalent chronic illness that is associated with substantial morbidity and increased all-cause mortality. The etiology of BD is complex, with multiple susceptibility genes likely responsible (1) .
Traditional mood-stabilizing therapies, alone or in combination with psychosocial interventions, beneficially influence full-blown mood episodes in BD. Notwithstanding, most treated BD patients remain symptomatic with significant functional morbidity (2) . Moreover, the effectiveness of lithium in usual clinical settings falls short of the efficacy results noted in rigorous controlled clinical trials (3, 4) . This uncoupling of effectiveness and efficacy results provides the impetus for effectiveness research with established and putative mood stabilizers (5) .
Several antiepileptic drugs are established as efficacious in BD (6, 7) . However, available data regarding the efficacy of topiramate in the treatment of BD are equivocal. Small, often single-centre, open-label studies suggest that this agent may be beneficial for the full mélange of BD symptoms. Nevertheless, 4 rigorous placebo-and comparator-controlled trials conducted in patients with acute mania failed to support the efficacy of topiramate as a monotherapy in this phase of the illness (8) .
Our investigation aimed to evaluate the effectiveness, safety, tolerability, and optimal dosing of topiramate in the treatment of BD patients who were not adequately responsive to treatment with lithium and (or) divalproex and other psychotropics and who were predominantly being treated in outpatient community clinics. Patients with unstable BD were selected on the basis of their continuing mood symptomatology and inadequate response to current therapy.
Methods
This 16-week study was conducted across Canada. Investigators (n = 17) were clinicians from both academic and community centres. All investigators received interrater reliability training for all effectiveness and safety metrics employed in the study. The study was conducted in accordance with the Declaration of Helsinki (http://www.fda.gov/oc/health/ helsinki89.html) and was approved by Health Canada, as well as by individual research ethics boards. Informed consent was obtained from each patient. Visits took place at baseline and at Weeks 2, 4, 8, 12, and 16.
Patients
Study participants were required to be outpatients, aged 16 years and over, meeting DSM-IV criteria for BD (type I or II). Patients suffering from psychosis were not eligible. Eligible patients were required to have had a historical minimum of 2 manic or depressive episodes in the previous 12 months. Moreover, eligible patients were required to be symptomatic as indicated by a YMRS total score of 13 or more or a MADRS total score of 12 or more, along with a CGI score of 4 or more. It was the clinician's determination that the patient was insufficiently responsive to either lithium or divalproex administered at a stable dosage (with recommended serum levels according to the 2001 Compendium of Pharmaceuticals and Specialties, 9) for a minimum of 4 weeks prestudy. Concomitant psychotropics (antipsychotics or antidepressants) were permitted if the dosage remained stable for at least 4 weeks before study enrolment and remained at a stable dosage throughout the patient's tenure in the study. Pregnant or lactating women or patients suffering from unstable medical illnesses were excluded. Exclusion criteria also did not permit the entry of patients with a primary DSM-IV Axis I diagnosis other than BD. Patients with alcohol or substance abuse or dependence were excluded, as were those with known sensitivity or contraindication to use of topiramate, lithium, or divalproex. Disallowed medications included herbal preparations, psychostimulants, carbamazepine, and carbonic anhydrase inhibitors.
Assessments
The primary effectiveness parameter was the CGI-S scale (10) . Secondary parameters were the YMRS (11) and the MADRS (12).
Tolerability was assessed through spontaneous adverse event reporting; monitoring of vital signs, body weight, and BMI; physical examination; clinical laboratory tests (biochemistry, hematology and urinalysis); and evaluation of tremor. A 10-cm VAS was used to measure tremor severity in patients with preexisting tremor.
A patient satisfaction questionnaire, based on a 5-point Likert scale ranging from a minimum of "completely dissatisfied" to a maximum of "completely satisfied" was also included to evaluate treatment satisfaction.
Dosing
Topiramate was initiated at 25 mg daily and titrated by an equal increment weekly, assuming tolerability, for the first 4 weeks. After Week 4, topiramate dosing could be increased by 50 mg weekly, not to exceed 400 mg daily. Patients were maintained at the highest tolerated and most effective dosage for a minimum of 1 month prior to study endpoint. Benzodiazepines were prescribed as rescue medications (up to lorazepam 4-mg equivalents daily).
Analyses
We categorized patients for analysis by mood symptoms based on baseline YMRS and MADRS score combinations as outlined in Table 1 .
The principal analyses of efficacy measures were conducted on an intent-to-treat basis. We included all participants who had at least one baseline assessment in the analyses. The Wilcoxon signed-rank test was used to analyze change from baseline. Significance was set at 2-tailed P < 0.05 by Scian Services Incorporated (Toronto, Ontario).
Results
A total of 70 patients (64%) completed the 16-week study. Table 2 lists patient demographics and baseline characteristics.
Study discontinuation occurred for the following reasons: adverse events, 11%; withdrawal of consent, 9%; lack of efficacy, 6%; protocol violation, 5%; missed study drug (> 5 days), 3%; lost to follow-up, 3%.
At baseline, 47 patients (43%) were receiving lithium, 48 patients (44%) were receiving divalproex, and 14 patients (13%) were receiving both lithium and divalproex. Patients could also be taking psychotropic medications if they had remained unchanged for at least 4 weeks prior to entry: 47 patients (43%) received an antipsychotic, and 45 patients (41%) concomitantly received an antidepressant.
The mean duration of topiramate use was 88 days, SD 37. The mean modal topiramate dosage for the total study was 145 mg daily, SD 92; during the stabilization period it was 180 mg daily, SD 89. The mean modal topiramate dosage was between 100 and 300 mg daily in 75 of 84 patients (89%) during the stable dosing period.
Efficacy CGI-S Results. For CGI-S results, please see Figure 1 .
YMRS and MADRS Results. Overall reductions in total YMRS scores in patients with mania and hypomania did not reach statistical significance, perhaps owing to the small sample sizes (n = 3 and n = 8, respectively). As a result, these 2 subgroups are not reported in the following sections.
Statistically significant reductions from baseline in mean YMRS score were noted in the mixed subgroup at all time points, starting at Week 2 (P < 0.001), and in the subgroup with depression from Week 8 onward (P < 0.001) ( Figure 2 ).
Statistically significant reductions from baseline mean MADRS score were noted in both the mixed subgroup and the subgroup with depression at all time points (P < 0.001), starting at Week 2 ( Figure 3 ).
At last observation, 19 of 42 patients (45%) in a mixed mood state at baseline, and 19 of 56 patients (34%) in a depressed mood state at baseline were in remission (total MADRS score 8 or less). Table 3 includes adverse events experienced by more than 10% of the patients.
Safety and Tolerability
At baseline, 39 patients (36%) had a clinically determined tremor, with a mean VAS severity score of 3.84, SD 2.7.
There was a significant reduction in the mean severity score by Week 8 (P < 0.005), which continued to last observation (P < 0.001). At endpoint, 8 of 37 patients (22%) no longer had tremors (2 patients had no postbaseline assessment for tremor). There were no clinically notable changes in physical examination results or in vital signs throughout the study. Overall, body weight (mean 84.9 kg, SD 21.1, at baseline) decreased by a mean of 1.8 kg, SD 3.2, at last observation (P < 0.001). The mean change in weight became statistically significant at the Week 8 study visit (-0.88 kg, SD 2.7, P < 0.001). At last observation, 24 patients (22%) had gained weight; 18 (17%) had no change in weight; and 65 (61%) had lost weight. More than 5% of body weight was lost by 22 patients (21%). For the total study sample, BMI was significantly reduced by Week 8 (P < 0.001), and at last observation the mean decrease was 0.66 kg / m 2 , SD 1.1 (P < 0.001). At baseline, 33 patients (51%) were obese (BMI = 30); 20 patients (31%) were overweight (BMI 25 to 29.9); and 12 patients (19%) were in the normal or acceptable weight category (BMI 18 to 25). At baseline, 1 patient had a GGT measure exceeding twice the upper limit of normal. At last observation, 2 patients had GGT exceeding twice the upper limit of normal; 1 patient had SGPT, SGOT, and cholesterol over twice the upper limit of normal. None of the patients had any other bioichemical indices that exceeded twice the upper limit of normal. No cases of metabolic acidosis were reported.
Patient Satisfaction
By the Week 2 visit, patient satisfaction with current medication improved significantly from baseline (P < 0.001) and continued to improve at each subsequent visit (Figure 4 ).
At baseline, 44 of 109 patients (40%) were "somewhat satisfied" or "completely satisfied" with their medication; 46 patients (42%) were "somewhat dissatisfied" or "completely dissatisfied" with their medication. At Week 16, 25 of 70 patients (36%) were "somewhat satisfied" and 35 patients (50%) were "completely satisfied" with treatment.
Discussion
Whereas traditional mood stabilizers such as lithium have proven efficacy in prophylactic treatment of BD I, sparse data support the use of any antibipolar therapy for subthreshold mood symptoms in the context of chronic biphasic mood instability.
This multicentre study suggests that adjunctive topiramate may safely benefit affective morbidity (notably, depression), weight, BMI, and tremor when employed for unstable BD patients. The interpretation of these findings is limited by several methodological deficiencies. This was a nonrandomized, open-label investigation without a placebo comparison group. This trial design is particularly vulnerable to patient and clinician expectancy factors. Moreover, the persistence and accrual of symptomatic benefit across the 4 months of observation militates against spontaneous improvement as a sufficient explanation for results obtained in this investigation.
Other variables that invite caution in interpreting these results include the heterogeneous patient mix and disparate assortments of pharmacologic agents prescribed. Although concomitant medications were to have been kept stable, response to these agents cannot be excluded. Although the patients in this study were recruited from outpatient clinic settings, the percentage of patients with comorbidity was conspicuously low, compared with current reports in the literature (13) . Nevertheless, the percentage of patients manifesting depressive symptoms as part of a depressed or mixed state in this series is similar to that in other observational studies (14, 15 ).
Topiramate's beneficial effect on body weight has been reported elsewhere in disparate patient populations (16, 17) . Patients with BD may have a higher frequency of overweight status; iatrogenic weight gain is a significant problem in this patient population (18, 19) . The weight loss associated with topiramate administration observed in this study, in addition to closer supervision and support, may have in fact contributed to increasing patients' motivation to comply with their treatment regimen.
Clinicians and researchers alike have noted that, although topiramate is inefficacious as monotherapy in cases if acute mania, it may be beneficial as an adjunctive agent for depressive or cyclicity-related symptoms.
It is established that both somatic and psychosocial treatment interventions in BD do not have equal efficacy across all phases of the illness. (20) (21) (22) (23) The high prevalence of patients with depressive symptoms enrolled in this study may indicate that these patients are the more difficult to treat in everyday clinical practice. Despite antidepressant use by many patients at baseline, there were continuing symptoms of depression that remitted with the use of topiramate in 42% of the depressed and mixed mood population. Treating bipolar depression with antidepressants of any class is complicated by the risk of manic switch or induced accelerated cycling (24) . No switches to mania were observed in this trial.
These data suggest that adjunctive topiramate may be beneficial for patients with unstable BD and persistent depressive symptoms. These results provide the impetus for randomized 
Figure 3 Mean total MADRS scores
There were significant reductions from baseline in total MADRS score by Week 2, with continued improvements through to the end of the 16-week study. All changes from baseline were statistically significant (P < 0.001) for the total sample, as well for patients in a mixed mood state or depressed mood state at baseline. 
Figure 2 Mean total YMRS scores
There were significant reductions from baseline in total YMRS score by Week 2, with continued improvements through to the end of the 16-week study. All changes from baseline were statistically significant (P < 0.001) for the total sample and in those patients with mixed mood symptoms at baseline. In those patients with depressed mood symptoms at baseline, the reduction in score was statistically significant at Week 8 (P < 0.05), Week 12 (P < 0.05), and Week 16 (P < 0.001).
trials of topiramate for acute bipolar depression and as a potential antirecurrence strategy for BD patients treated with established and putative somatic and psychosocial therapies.
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Figure 4 Mean patient satisfaction with medication scores
There were significant improvements in patient satisfaction scores by Week 2, with continued improvements to Week 12 that were maintained at Week 16. The scale ranged from a score of 1 = "completely dissatisfied," to a score of 5 = "completely satisfied." All changes from baseline were statistically significant (P < 0.001).
